[1] LIANG X, BI S, YANG W, et al. Epi-demiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27 (47) :6550-6557.
|
[2] NI YH, CHANG MH, HUANG LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area:15 years after mass hepatitis B vaccination[J]. Ann Intern Med, 2001, 135 (9) :796-800.
|
[3] ZHANG L, XU A, YAN B, et al. A significant reduction in hepatitis B virus infection among the children of Shandong Province, China:The effect of 15 years of universal infant hepatitis B vaccination[J]. Int J Infect Dis, 2010, 14 (6) :e483-e488.
|
[4] LAI CL, RATZIU V, YUEN MF, et al. Viral hepatitis B[J]. Lancet, 2003, 362 (9401) :2089-2094.
|
[5] JONAS MM. Hepatitis B and pregnancy:An underestimated issue[J]. Liver Int, 2009, 29 (Suppl 1) :133-139.
|
[6] HAN GR, XU CL, ZHAO W, et al. Management of chronic hepatitis B in pregnancy[J]. World J Gastroenterol, 2012, 18 (33) :4517-4521.
|
[7] PETERSEN J. HBV treatment and pregnancy[J]. J Hepatol, 2011, 55 (6) :1171-1173.
|
[8] HAN GR, CAO MK, ZHAO W, et al. A prospective and open label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol, 2011, 55 (6) :1215-1221.
|
[9] ZHANG H, PAN CALVIN Q, PANG QM, et al. Telbivudine or lamivudineuse in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-lifepractice[J]. Hepatology, 2014, 60 (2) :468-476.
|
[10] DIENSTAG JL, SCHIFF ER, WRIGHT TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States[J].N Engl J Med, 1999, 341 (17) :1256-1263.
|
[11] MAST EE, MARGOLIS HS, FIORE AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States:Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1:immunization of infants, children, and adolescents[J]. MMWR Recomm Rep, 2005, 54 (RR-16) :1-31.
|
[12] PAN CQ, HAN GR, JIANG HX, et al. Telbivudine prevents vertical transmission from HBe Ag-positive women with chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2012, 10 (5) :520-526.
|
[13] GANE EJ, DERAY G, LIAW YF, et al. Telbivudine improves renal function in patients with hepatitis B[J]. Gastroenterology, 2014, 146 (1) :138-146. e5.
|
[14] SUN J, XIE Q, TAN D, et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients:A randomized, controlled study[J].Hepatology, 2014, 59 (4) :1283-1292.
|
[15] HAN GR, JIANG HX, YUE X, et al. Efficacy and safety of telbivudine treatment:An open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Viral Hepat, 2015, 22 (9) :754-762.
|
[16] HAN GR, JIANG HX, WANG CM, et al. Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy[J]. J Viral Hepat, 2017, 24 (6) :514-521.
|
[17] PAN CQ, DUAN Z, DAI E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374 (24) :2324-2334.
|